1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Corvus Pharmaceuticals, Inc.US flagNASDAQ Global Market
11.60
USD
-0.09
- -
975.45MMarket Cap
Corvus Pharmaceuticals, Inc.
CRVS
(NASDAQ Global Market)

Recent

price

11.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-1.54
-2.36
-2.72
-1.71
-1.59
-0.2
-1.03
-0.89
-0.56
-1.02
- -
-0.53
Basic EPS, GAAP
- -
-0.64
-1.95
-2.27
-1.5
-1.27
-1.18
-0.88
-0.59
-0.5
-0.42
- -
-0.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-1.54
-4.4
-6.03
-6.2
-7.4
-7.57
-6.36
-6.61
-6.97
-6.51
- -
-5.11
Book Value per Share
- -
-1.52
8.61
4.14
4.01
2.42
2.45
2.32
1.21
0.81
0.53
- -
2.89
Tangible Book Value per Share
- -
20
15
20
28
29
29
42
47
48
61
- -
83
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
1
1
1
1
1
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-31
-36
-56
-47
-47
-6
-43
-41
-27
-62
-15
-44
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
10
93
130
82
109
69
33
62
33
21
19
49
228
Working Capital
- -
- -
- -
- -
- -
2
1
3
1
- -
1
1
- -
LT Debt
- -
-31
133
85
110
71
72
97
56
39
33
61
241
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
75
75
84
Market Capitalization
555
608
1,220

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
67
58
240
Cash, Cash Equivalents & STI
66
57
237
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
9
12
Payables & Accruals
6
8
10
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-53.37%
6.7%
87.93%
Free Cash Flow
16.04%
0.65%
29.68%
Net Income, GAAP
60.29%
127.45%
-75.47%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.07
-0.6
-0.18
-1.02
2025
0.21
-0.1
-0.12
-0.15
- -
2026
-0.15
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PharmaResearch Co., Ltd. (214450.KQ)
Valerio Therapeutics S.A. (ALVIO.PA)
CASI Pharmaceuticals, Inc. (CASIF)
Beijing Scitop Bio-tech Co., Ltd. (300858.SZ)
Asarina Pharma AB (publ) (ASRPF)
Synthaverse S.A. (SVE.WA)
Business
Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company focused on developing novel ITK inhibition therapies and immuno-oncology agents to treat cancer and immune diseases. The company offers soquelitinib (CPI-818), a first-in-class oral selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) for relapsed/refractory peripheral T-cell lymphoma (PTCL), moderate-to-severe atopic dermatitis, autoimmune lymphoproliferative syndrome (ALPS), and planned applications in metastatic renal cell cancer (RCC); ciforadenant (CPI-444), an oral small-molecule antagonist of the adenosine A2A receptor for advanced RCC in combination with ipilimumab and nivolumab; and mupadolimab (CPI-006), a humanized monoclonal anti-CD73 antibody evaluated in non-small cell lung cancer that promotes adenosine blockade and B-cell activation. Incorporated in 2014 and headquartered in Burlingame, California, Corvus conducts operations primarily in the United States with a strategic collaboration partner, Angel Pharmaceuticals Co. Ltd. in China, for soquelitinib in T-cell lymphomas and mupadolimab commercialization. In recent developments, Corvus completed enrollment in extension Cohort 4 of its Phase 1/1b trial of soquelitinib in refractory T-cell lymphomas, with full dataset results, including 8-week data from 24 atopic dermatitis patients, expected in January 2026 ahead of an ASH conference presentation on T-cell lymphoma data; the company plans to initiate a Phase 2 trial in atopic dermatitis and a Phase 1b/2 trial in RCC in early 2026. Interim Phase 1 data from soquelitinib in atopic dermatitis demonstrated a favorable safety and efficacy profile in moderate-to-severe patients. Financially, Corvus narrowed its Q3 2025 net loss to $10.2 million from $40.2 million year-over-year, driven by R&D investments, while maintaining focus on partnerships and pipeline expansion amid ongoing Phase 3 PTCL evaluation.

Company News

APIChat

  • globenewswire.com

    Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

  • seekingalpha.com

    Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early

  • fool.com

    Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

  • seekingalpha.com

    Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call Transcript

  • globenewswire.com

    Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

  • globenewswire.com

    Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

  • globenewswire.com

    Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D.

  • globenewswire.com

    Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

  • defenseworld.net

    Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Moderate Buy” by Analysts

  • defenseworld.net

    Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings

  • seekingalpha.com

    Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript

  • globenewswire.com

    Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

  • globenewswire.com

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

  • globenewswire.com

    Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • marketbeat.com

    Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

  • zacks.com

    Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why

  • zacks.com

    Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know

  • zacks.com

    Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

  • globenewswire.com

    Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

  • defenseworld.net

    Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains